Treatment of both native and deamidated gluten peptides with an endo-peptidase from Aspergillus niger prevents stimulation of gut-derived gluten-reactive T cells from either children or adults with celiac disease

Clinical Immunology

Volumn 153, Issue 2, 2014, Pages 323-331

  Toft Hansen, Henrik ^a   Rasmussen, Karina S ^a   Staal, Anne ^a   Roggen, Erwin L ^b   Sollid, Ludvig M ^c   Lillevang, Søren T ^a   Barington, Torben ^a   Husby, Steffen ^a  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

^b NOVOZYMES A S   (Denmark)

^c UNIVERSITY OF OSLO   (Norway)

Author keywords

Autoimmunity; ; Celiac disease; ; Gluten; ; Proteases

Indexed keywords

ASPERGILLUS NIGER PROTEASE 2; BACTERIAL ENZYME; GLIADIN; GLUTEN; PROTEINASE; UNCLASSIFIED DRUG;

ARTICLE; ASPERGILLUS NIGER; ASPERGILLUS ORYZAE; B LYMPHOCYTE; BACILLUS AMYLOLIQUEFACIENS; BACILLUS LICHENIFORMIS; CD4+ T LYMPHOCYTE; CELIAC DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DEAMINATION; DIET SUPPLEMENTATION; DUODENUM BIOPSY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNITY; IN VITRO STUDY; LYMPHOCYTE PROLIFERATION; PRIORITY JOURNAL; RHIZOMUCOR MIEHEI; T LYMPHOCYTE; THERMOASCUS;

AUTOIMMUNITY;; CELIAC DISEASE;; GLUTEN;; PROTEASES;

ADULT; AMINO ACID SEQUENCE; ASPERGILLUS NIGER; CD4-POSITIVE T-LYMPHOCYTES; CELIAC DISEASE; CELL LINE; CELL PROLIFERATION; CHILD; CLONE CELLS; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ENDOPEPTIDASES; FUNGAL PROTEINS; GLUTENS; HUMANS; INTESTINES; MOLECULAR SEQUENCE DATA; PEPTIDES; SUBSTRATE SPECIFICITY;

EID: 84902658394     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2014.05.009     Document Type: Article

References (42)

1. Abadie V., Sollid L.M., Barreiro L.B., Jabri B. Integration of genetic and immunological insights into a model of celiac disease pathogenesis. Annu. Rev. Immunol. 2011, 29:493-525.
2. Arentz-Hansen H., McAdam S.N., Molberg O., Fleckenstein B., Lundin K.E., Jorgensen T.J., Jung G., Roepstorff P., Sollid L.M. Celiac lesion T cells recognize epitopes that cluster in regions of gliadins rich in proline residues. Gastroenterology 2002, 123:803-809.
3. Caputo I., Lepretti M., Martucciello S., Esposito C. Enzymatic strategies to detoxify gluten: implications for celiac disease. Enzym. Res. 2010, 2010:174354.
4. Crespo Perez L., Castillejo de Villasante G., Cano Ruiz A., Leon F. Non-dietary therapeutic clinical trials in coeliac disease. Eur. J. Intern. Med. 2012, 23:9-14.
5. Dahlbom I., Korponay-Szabo I.R., Kovacs J.B., Szalai Z., Maki M., Hansson T. Prediction of clinical and mucosal severity of coeliac disease and dermatitis herpetiformis by quantification of IgA/IgG serum antibodies to tissue transglutaminase. J. Pediatr. Gastroenterol. Nutr. 2010, 50:140-146.
6. Di Sabatino A., Corazza G.R. Coeliac disease. Lancet 2009, 373:1480-1493.
7. Dydensborg S., Toftedal P., Biaggi M., Lillevang S.T., Hansen D.G., Husby S. Increasing prevalence of coeliac disease in Denmark: a linkage study combining national registries. Acta Paediatr. 2012, 101:179-184.
8. Fasano A., Berti I., Gerarduzzi T., Not T., Colletti R.B., Drago S., Elitsur Y., Green P.H., Guandalini S., Hill I.D., Pietzak M., Ventura A., Thorpe M., Kryszak D., Fornaroli F., Wasserman S.S., Murray J.A., Horvath K. Prevalence of celiac disease in at-risk and not-at-risk groups in the United States: a large multicenter study. Arch. Intern. Med. 2003, 163:286-292.
9. Gass J., Bethune M.T., Siegel M., Spencer A., Khosla C. Combination enzyme therapy for gastric digestion of dietary gluten in patients with celiac sprue. Gastroenterology 2007, 133:472-480.
10. Gass J., Vora H., Bethune M.T., Gray G.M., Khosla C. Effect of barley endoprotease EP-B2 on gluten digestion in the intact rat. J. Pharmacol. Exp. Ther. 2006, 318:1178-1186.
11. Hausch F., Shan L., Santiago N.A., Gray G.M., Khosla C. Intestinal digestive resistance of immunodominant gliadin peptides. Am. J. Physiol. Gastrointest. Liver Physiol. 2002, 283:G996-G1003.
12. Lahdeaho M.L., Kaukinen K., Laurila K., Vuotikka P., Koivurova O.P., Karja-Lahdensuu T., Marcantonio A., Adelman D.C., Maki M. Glutenase ALV003 attenuates gluten-induced mucosal injury in patients with celiac disease. Gastroenterology 2014, Jun, 146(7):1649-1658. Epub 2014 Feb 25. 10.1053/j.gastro.2014.02.031.
13. Lerner A. New therapeutic strategies for celiac disease. Autoimmun. Rev. 2010, 9:144-147.
14. Lin M.Y., Dipalma J.A., Martini M.C., Gross C.J., Harlander S.K., Savaiano D.A. Comparative effects of exogenous lactase (beta-galactosidase) preparations on in vivo lactose digestion. Dig. Dis. Sci. 1993, 38:2022-2027.
15. Littlewood J.M., Wolfe S.P., Conway S.P. Diagnosis and treatment of intestinal malabsorption in cystic fibrosis. Pediatr. Pulmonol. 2006, 41:35-49.
16. Maki M., Mustalahti K., Kokkonen J., Kulmala P., Haapalahti M., Karttunen T., Ilonen J., Laurila K., Dahlbom I., Hansson T., Hopfl P., Knip M. Prevalence of celiac disease among children in Finland. N. Engl. J. Med. 2003, 348:2517-2524.
17. Marti T., Molberg O., Li Q., Gray G.M., Khosla C., Sollid L.M. Prolyl endopeptidase-mediated destruction of T cell epitopes in whole gluten: chemical and immunological characterization. J. Pharmacol. Exp. Ther. 2005, 312:19-26.
18. Mitea C., Havenaar R., Drijfhout J.W., Edens L., Dekking L., Koning F. Efficient degradation of gluten by a prolyl endoprotease in a gastrointestinal model: implications for coeliac disease. Gut 2008, 57:25-32.
19. Molberg O., McAdam S.N., Korner R., Quarsten H., Kristiansen C., Madsen L., Fugger L., Scott H., Noren O., Roepstorff P., Lundin K.E., Sjostrom H., Sollid L.M. Tissue transglutaminase selectively modifies gliadin peptides that are recognized by gut-derived T cells in celiac disease. Nat. Med. 1998, 4:713-717.
20. Molberg O., McAdam S.N., Lundin K.E., Sollid L.M. Studies of gliadin-specific T-cells in celiac disease. Meth. Mol. Med. 2000, 41:105-124.
21. Mustalahti K., Catassi C., Reunanen A., Fabiani E., Heier M., McMillan S., Murray L., Metzger M.H., Gasparin M., Bravi E., Maki M., Coeliac Eu Cluster P.E. The prevalence of celiac disease in Europe: results of a centralized, international mass screening project. Ann. Med. 2010, 42:587-595.
22. Piper J.L., Gray G.M., Khosla C. Effect of prolyl endopeptidase on digestive-resistant gliadin peptides in vivo. J. Pharmacol. Exp. Ther. 2004, 311:213-219.
23. Pyle G.G., Paaso B., Anderson B.E., Allen D.D., Marti T., Li Q., Siegel M., Khosla C., Gray G.M. Effect of pretreatment of food gluten with prolyl endopeptidase on gluten-induced malabsorption in celiac sprue. Clin. Gastroenterol. Hepatol. 2005, 3:687-694.
24. Qiao S.W., Sollid L.M., Blumberg R.S. Antigen presentation in celiac disease. Curr. Opin. Immunol. 2009, 21:111-117.
25. Shan L., Molberg O., Parrot I., Hausch F., Filiz F., Gray G.M., Sollid L.M., Khosla C. Structural basis for gluten intolerance in celiac sprue. Science 2002, 297:2275-2279.
26. Siegel M., Bethune M.T., Gass J., Ehren J., Xia J., Johannsen A., Stuge T.B., Gray G.M., Lee P.P., Khosla C. Rational design of combination enzyme therapy for celiac sprue. Chem. Biol. 2006, 13:649-658.
27. Siegel M., Garber M.E., Spencer A.G., Botwick W., Kumar P., Williams R.N., Kozuka K., Shreeniwas R., Pratha V., Adelman D.C. Safety, tolerability, and activity of ALV003: results from two phase 1 single, escalating-dose clinical trials. Dig. Dis. Sci. 2012, 57:440-450.
28. Siegel M., Strnad P., Watts R.E., Choi K., Jabri B., Omary M.B., Khosla C. Extracellular transglutaminase 2 is catalytically inactive, but is transiently activated upon tissue injury. PLoS One 2008, 3:e1861.
29. Sollid L.M. Coeliac disease: dissecting a complex inflammatory disorder. Nat. Rev. Immunol. 2002, 2:647-655.
30. Sollid L.M., Jabri B. Triggers and drivers of autoimmunity: lessons from coeliac disease. Nat. Rev. Immunol. 2013, 13:294-302.
31. Sollid L.M., Khosla C. Novel therapies for coeliac disease. J. Intern. Med. 2011, 269:604-613.
32. Stenman S.M., Venalainen J.I., Lindfors K., Auriola S., Mauriala T., Kaukovirta-Norja A., Jantunen A., Laurila K., Qiao S.W., Sollid L.M., Mannisto P.T., Kaukinen K., Maki M. Enzymatic detoxification of gluten by germinating wheat proteases: implications for new treatment of celiac disease. Ann. Med. 2009, 41:390-400.
33. Stepniak D., Koning F. Enzymatic gluten detoxification: the proof of the pudding is in the eating!. Trends Biotechnol. 2006, 24:433-434.
34. Stepniak D., Spaenij-Dekking L., Mitea C., Moester M., de Ru A., Baak-Pablo R., van Veelen P., Edens L., Koning F. Highly efficient gluten degradation with a newly identified prolyl endoprotease: implications for celiac disease. Am. J. Physiol. Gastrointest. Liver Physiol. 2006, 291:G621-G629.
35. Stern M., Ciclitira P.J., van Eckert R., Feighery C., Janssen F.W., Mendez E., Mothes T., Troncone R., Wieser H. Analysis and clinical effects of gluten in coeliac disease. Eur. J. Gastroenterol. Hepatol. 2001, 13:741-747.
36. Tack G.J., van de Water J.M., Bruins M.J., Kooy-Winkelaar E.M., van Bergen J., Bonnet P., Vreugdenhil A.C., Korponay-Szabo I., Edens L., von Blomberg B.M., Schreurs M.W., Mulder C.J., Koning F. Consumption of gluten with gluten-degrading enzyme by celiac patients: a pilot-study. World J. Gastroenterol. 2013, 19:5837-5847.
37. Tye-Din J.A., Anderson R.P., Ffrench R.A., Brown G.J., Hodsman P., Siegel M., Botwick W., Shreeniwas R. The effects of ALV003 pre-digestion of gluten on immune response and symptoms in celiac disease in vivo. Clin. Immunol. 2010, 134:289-295.
38. Tye-Din J.A., Stewart J.A., Dromey J.A., Beissbarth T., van Heel D.A., Tatham A., Henderson K., Mannering S.I., Gianfrani C., Jewell D.P., Hill A.V., McCluskey J., Rossjohn J., Anderson R.P. Comprehensive, quantitative mapping of T cell epitopes in gluten in celiac disease. Sci. Transl. Med. 2010, 2:41ra51.
39. Vader W., Kooy Y., Van Veelen P., De Ru A., Harris D., Benckhuijsen W., Pena S., Mearin L., Drijfhout J.W., Koning F. The gluten response in children with celiac disease is directed toward multiple gliadin and glutenin peptides. Gastroenterology 2002, 122:1729-1737.
40. van Overbeek F.M., Uil-Dieterman I.G., Mol I.W., Kohler-Brands L., Heymans H.S., Mulder C.J. The daily gluten intake in relatives of patients with coeliac disease compared with that of the general Dutch population. Eur. J. Gastroenterol. Hepatol. 1997, 9:1097-1099.
41. Weiner H.L., da Cunha A.P., Quintana F., Wu H. Oral tolerance. Immunol. Rev. 2011, 241:241-259.
42. Zamakhchari M., Wei G., Dewhirst F., Lee J., Schuppan D., Oppenheim F.G., Helmerhorst E.J. Identification of Rothia bacteria as gluten-degrading natural colonizers of the upper gastro-intestinal tract. PLoS One 2011, 6:e24455.